JP2022501336A5 - - Google Patents
Info
- Publication number
- JP2022501336A5 JP2022501336A5 JP2021514344A JP2021514344A JP2022501336A5 JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5 JP 2021514344 A JP2021514344 A JP 2021514344A JP 2021514344 A JP2021514344 A JP 2021514344A JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- optionally
- phytosterols
- seq
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731335P | 2018-09-14 | 2018-09-14 | |
| US62/731,335 | 2018-09-14 | ||
| US201862770024P | 2018-11-20 | 2018-11-20 | |
| US62/770,024 | 2018-11-20 | ||
| US201962881322P | 2019-07-31 | 2019-07-31 | |
| US62/881,322 | 2019-07-31 | ||
| PCT/US2019/051072 WO2020056304A1 (en) | 2018-09-14 | 2019-09-13 | Methods and compositions for treating cancer using mrna therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501336A JP2022501336A (ja) | 2022-01-06 |
| JP2022501336A5 true JP2022501336A5 (enExample) | 2022-09-20 |
| JP7556848B2 JP7556848B2 (ja) | 2024-09-26 |
Family
ID=68104746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514344A Active JP7556848B2 (ja) | 2018-09-14 | 2019-09-13 | ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230081530A1 (enExample) |
| EP (1) | EP3849589A1 (enExample) |
| JP (1) | JP7556848B2 (enExample) |
| CN (1) | CN113015540A (enExample) |
| AU (1) | AU2019338535A1 (enExample) |
| CA (1) | CA3112781A1 (enExample) |
| WO (1) | WO2020056304A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| JP2022543773A (ja) * | 2019-07-31 | 2022-10-14 | モデルナティエックス インコーポレイテッド | 免疫細胞へのｒｎａ干渉剤の送達のための組成物及び方法 |
| JP2023526059A (ja) * | 2020-05-14 | 2023-06-20 | モダーナティエックス・インコーポレイテッド | ｍＲＮＡ治療薬及びエフェクター分子を含むＬＮＰ組成物 |
| CA3178965A1 (en) | 2020-05-15 | 2021-11-18 | Christian COBAUGH | Messenger rna encoding cas9 for use in genome-editing systems |
| WO2022010764A1 (en) * | 2020-07-06 | 2022-01-13 | Vivtex Corporation | Mucopenetrating formulations |
| CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| WO2022120560A1 (zh) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| US20240200106A1 (en) * | 2021-04-17 | 2024-06-20 | Intellia Thrapeutics, Inc. | Lipid nanoparticles compositions |
| WO2022228492A1 (zh) * | 2021-04-29 | 2022-11-03 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| WO2022240960A1 (en) | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
| US12251471B2 (en) * | 2021-07-26 | 2025-03-18 | Oregon State University | Inhalable therapeutics |
| CN114457054A (zh) * | 2022-02-24 | 2022-05-10 | 中国科学技术大学 | 一种cGAS mRNA的制备及作为免疫激活剂的应用 |
| US20250312430A1 (en) * | 2022-03-30 | 2025-10-09 | The Johns Hopkins University | Compositions of lipid nanoparticles for plasmid dna delivery to the liver and methods for preparing the same |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| US20250375502A1 (en) * | 2022-06-22 | 2025-12-11 | Wuhan Houxian Biopharmaceutical Co. Ltd. | Combination of il-12 and ox40l for cancer immunotherapy |
| CA3262115A1 (en) * | 2022-07-15 | 2024-01-18 | President And Fellows Of Harvard College | MUCISPIRILLUM COMPOSITIONS AND ASSOCIATED CANCER TREATMENT METHODS |
| WO2024032613A1 (zh) * | 2022-08-09 | 2024-02-15 | 斯微(上海)生物科技股份有限公司 | 一种脂质组合物 |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| EP4649087A2 (en) | 2023-01-11 | 2025-11-19 | Engage Biologics Inc. | Non-viral expression systems and methods of use thereof |
| EP4470559A1 (en) * | 2023-06-02 | 2024-12-04 | Imgen-T-Srl | Combination containing an mrna vaccine and an immune modulating mrna for improved immunogenicity and efficacy |
| WO2025098508A1 (zh) * | 2023-11-10 | 2025-05-15 | 贝达药业股份有限公司 | 标记性多肽、治疗剂及其应用 |
| CN119662655A (zh) * | 2023-12-04 | 2025-03-21 | 武汉厚先生物医药有限公司 | Rna分子及其组合物在肿瘤免疫治疗中的应用 |
| WO2026078565A1 (en) | 2024-10-10 | 2026-04-16 | Crispr Therapeutics Ag | Messenger rna encoding cas9 for use in genome-editing systems |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2462144C (en) | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Micro-rna molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| EP2530157B1 (en) | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2691785C (en) * | 2007-06-27 | 2017-01-10 | Marine Polymer Technologies Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| EP3156414B1 (en) | 2007-09-26 | 2019-12-04 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| TR201811076T4 (tr) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP5902197B2 (ja) | 2011-01-11 | 2016-04-13 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | Ｐｅｇ化脂質および薬剤送達のためのそれらの使用 |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| IL316479A (en) | 2014-06-25 | 2024-12-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| WO2016048903A1 (en) * | 2014-09-22 | 2016-03-31 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| EP3173092B1 (en) * | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| RS63986B1 (sr) | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| CA3007955A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
| WO2017112943A1 (en) * | 2015-12-23 | 2017-06-29 | Modernatx, Inc. | Methods of using ox40 ligand encoding polynucleotides |
| DK3458083T5 (da) * | 2016-05-18 | 2024-10-21 | Modernatx Inc | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf |
| WO2017201325A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| EP3458092A1 (en) * | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| CN110267978A (zh) * | 2016-10-07 | 2019-09-20 | 得克萨斯大学体系董事会 | 用于治疗癌症的表达膜锚定的il-12的t细胞 |
| US11421011B2 (en) * | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| US20190314291A1 (en) * | 2018-01-30 | 2019-10-17 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
-
2019
- 2019-09-13 EP EP19780053.5A patent/EP3849589A1/en active Pending
- 2019-09-13 CN CN201980074987.2A patent/CN113015540A/zh active Pending
- 2019-09-13 AU AU2019338535A patent/AU2019338535A1/en not_active Abandoned
- 2019-09-13 WO PCT/US2019/051072 patent/WO2020056304A1/en not_active Ceased
- 2019-09-13 CA CA3112781A patent/CA3112781A1/en active Pending
- 2019-09-13 US US17/275,832 patent/US20230081530A1/en not_active Abandoned
- 2019-09-13 JP JP2021514344A patent/JP7556848B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Advances in immunotherapy for triple-negative breast cancer | |
| US8367628B2 (en) | Amphoteric liposome formulation | |
| JP2020520640A5 (enExample) | ||
| JP2023552195A5 (enExample) | ||
| CN104903450A (zh) | 寡核苷酸癌症疗法的给药和施用 | |
| EP3603748A1 (en) | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer | |
| JP5623016B2 (ja) | 癌治療法およびそれに用いる医薬組成物 | |
| JP2020111589A (ja) | リポソーム製剤 | |
| Fan et al. | Lipid-based nanoparticles for cancer immunotherapy | |
| JP2022188159A (ja) | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 | |
| CN104884637A (zh) | 利用生物标志物通过bcl2表达的调节治疗癌症的方法 | |
| CN108310378A (zh) | 一类新型免疫联体抗肿瘤创新药物的制备及其应用 | |
| JP2022525223A (ja) | ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療 | |
| TW202114647A (zh) | 用於治療具有高間質壓力的腫瘤受試者的癌症的小分子抑制劑 | |
| EP4031873A1 (en) | Quantitative spatial profiling for lag-3 antagonist therapy | |
| TWI760319B (zh) | 乳癌治療 | |
| KR20240158980A (ko) | 유기 화합물 | |
| WO2009051712A1 (en) | Dnai amphoteric liposome formulation | |
| US20260000757A1 (en) | Combination therapy for lung cancer | |
| AU2023226175A1 (en) | Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof | |
| WO2007065017A2 (en) | Oligonucleotide cationic liposomal delivery system | |
| WO2020160409A1 (en) | Methods of treating cancer using a combination of tumor membrane vesicles and metformin | |
| WO2022097634A1 (ja) | 血管新生依存性疾患治療に使用される医薬用組成物 | |
| CN116621966B (zh) | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 | |
| Le et al. | Therapeutic Management of Lymphoma: Conventional Strategies and Overcoming Treatment Barriers with Nanotherapeutics |